Leora Horn1, Scott N Gettinger2, Michael S Gordon3, Roy S Herbst2, Leena Gandhi4, Enriqueta Felip5, Lecia V Sequist6, David R Spigel7, Scott J Antonia8, Ani Balmanoukian9, Philippe A Cassier10, Bo Liu11, Marcin Kowanetz11, Carol O'Hear11, Marcella Fassò11, William Grossman11, Alan Sandler11, Jean-Charles Soria12. 1. Vanderbilt-Ingram Cancer Center, Nashville, TN, USA. Electronic address: leora.horn@vanderbilt.edu. 2. Yale Comprehensive Cancer Center, Yale School of Medicine, New Haven, CT, USA. 3. HonorHealth Research Institute, Scottsdale, AZ, USA. 4. Dana-Farber Cancer Institute, Boston, MA, USA. 5. Vall D'Hebron University Hospital, Barcelona, Spain. 6. Massachusetts General Hospital Cancer Center, Boston, MA, USA. 7. Sarah Cannon Research Institute and Cancer Center, Tennessee Oncology, Nashville, TN, USA. 8. H. Lee Moffitt Cancer Center, Tampa, FL, USA. 9. The Angeles Clinic and Research Institute, Los Angeles, CA, USA. 10. Centre Léon-Bérard, Lyon, France. 11. Genentech, Inc., South San Francisco, CA, USA. 12. Gustave Roussy and University Paris-Sud, Villejuif, France.
Abstract
INTRODUCTION: Atezolizumab, an anti-programmed death-ligand 1 (PD-L1) antibody, inhibits PD-L1:PD-1 and PD-L1:B7.1 interactions, restoring anticancer immunity. Here, we report final analyses from the non-small-cell lung cancer (NSCLC) cohort of the first atezolizumab phase I study. METHODS: Patients with NSCLC received atezolizumab 1-20 mg/kg or 1200 mg intravenously every 3 weeks. Baseline PD-L1 expression on tumour cells (TCs) and tumour-infiltrating immune cells (ICs) was assessed (VENTANA SP142 immunohistochemistry assay). Exploratory subgroup analyses investigated responses by baseline PD-L1 expression and oncogenic mutational status. RESULTS: Eighty-nine patients, 98% of whom had received previous systemic therapy, were evaluable for safety and antitumour activity. Atezolizumab was well tolerated, with grade III/IV treatment-related adverse events (TRAEs) observed in 10 patients (11%). All-grade TRAEs occurring in >10% of patients were fatigue, nausea and decreased appetite; grade III/IV TRAEs occurring in >2% of patients were fatigue, dyspnoea, hyponatremia and hypoxia. One patient died from treatment-unrelated pneumonia. Objective response rate (ORR) was 50% (95% confidence interval [CI], 28%-72%), 33% (20%-48%), 29% (18%-41%) and 11% (1%-35%) for the TC3 or IC3, TC2/3 or IC2/3, TC1/2/3 or IC1/2/3 and TC0 and IC0 subgroups, respectively. All-patient ORR was 23% (95% CI, 14%-33%). Median duration of response was 16.4 months (range, 7.2-53.4+). One-, 2-, and 3-year survival rates were 63% (95% CI, 53%-73%), 37% (26%-47%) and 28% (18%-38%), respectively. CONCLUSIONS: Single-agent atezolizumab was well tolerated with long-term clinical benefits, including durable responses and survival, in pretreated NSCLC. Improved responses and survival rates were seen with increasing baseline PD-L1 expression. CLINICALTRIALS. GOV IDENTIFIER: NCT01375842.
INTRODUCTION:Atezolizumab, an anti-programmed death-ligand 1 (PD-L1) antibody, inhibits PD-L1:PD-1 and PD-L1:B7.1 interactions, restoring anticancer immunity. Here, we report final analyses from the non-small-cell lung cancer (NSCLC) cohort of the first atezolizumab phase I study. METHODS:Patients with NSCLC received atezolizumab 1-20 mg/kg or 1200 mg intravenously every 3 weeks. Baseline PD-L1 expression on tumour cells (TCs) and tumour-infiltrating immune cells (ICs) was assessed (VENTANA SP142 immunohistochemistry assay). Exploratory subgroup analyses investigated responses by baseline PD-L1 expression and oncogenic mutational status. RESULTS: Eighty-nine patients, 98% of whom had received previous systemic therapy, were evaluable for safety and antitumour activity. Atezolizumab was well tolerated, with grade III/IV treatment-related adverse events (TRAEs) observed in 10 patients (11%). All-grade TRAEs occurring in >10% of patients were fatigue, nausea and decreased appetite; grade III/IV TRAEs occurring in >2% of patients were fatigue, dyspnoea, hyponatremia and hypoxia. One patient died from treatment-unrelated pneumonia. Objective response rate (ORR) was 50% (95% confidence interval [CI], 28%-72%), 33% (20%-48%), 29% (18%-41%) and 11% (1%-35%) for the TC3 or IC3, TC2/3 or IC2/3, TC1/2/3 or IC1/2/3 and TC0 and IC0 subgroups, respectively. All-patient ORR was 23% (95% CI, 14%-33%). Median duration of response was 16.4 months (range, 7.2-53.4+). One-, 2-, and 3-year survival rates were 63% (95% CI, 53%-73%), 37% (26%-47%) and 28% (18%-38%), respectively. CONCLUSIONS: Single-agent atezolizumab was well tolerated with long-term clinical benefits, including durable responses and survival, in pretreated NSCLC. Improved responses and survival rates were seen with increasing baseline PD-L1 expression. CLINICALTRIALS. GOV IDENTIFIER: NCT01375842.
Authors: Mathilde Marchand; Rong Zhang; Phyllis Chan; Valerie Quarmby; Marcus Ballinger; Nitzan Sternheim; Benjamin Wu; Jin Y Jin; René Bruno Journal: Cancer Chemother Pharmacol Date: 2021-04-27 Impact factor: 3.333
Authors: Deborah B Doroshow; Miguel F Sanmamed; Katherine Hastings; Katerina Politi; David L Rimm; Lieping Chen; Ignacio Melero; Kurt A Schalper; Roy S Herbst Journal: Clin Cancer Res Date: 2019-03-01 Impact factor: 12.531
Authors: Yucai Wang; Shouhao Zhou; Fang Yang; Xinyue Qi; Xin Wang; Xiaoxiang Guan; Chan Shen; Narjust Duma; Jesus Vera Aguilera; Ashish Chintakuntlawar; Katharine A Price; Julian R Molina; Lance C Pagliaro; Thorvardur R Halfdanarson; Axel Grothey; Svetomir N Markovic; Grzegorz S Nowakowski; Stephen M Ansell; Michael L Wang Journal: JAMA Oncol Date: 2019-07-01 Impact factor: 31.777
Authors: Marcus A Couey; R Bryan Bell; Ashish A Patel; Meghan C Romba; Marka R Crittenden; Brendan D Curti; Walter J Urba; Rom S Leidner Journal: J Immunother Cancer Date: 2019-07-03 Impact factor: 13.751